A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-05-03
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-09 (study day 20); relationship: not assessed
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-07-28 (study day 69); relationship: N
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-20 (study day 92); relationship: not assessed
Data queries
No data queries.